Six Against the Scientists: An FDA Panel Backs Peptides With No Clinical Track Record

The vote matters because the substances in question are already being injected by thousands of Americans who buy them on the gray market, promoted online for everything from torn ligaments to sharper focus. What the panel did, in effect, was take a demand that has been building outside the medical system and bring it inside the pharmacy counter.

The Pharmacy Compounding Advisory Committee advises the FDA on which bulk drug substances should be available to compounding pharmacists under Section 503A of the Federal Food, Drug, and Cosmetic Act. Inclusion on the list is the regulatory handshake that lets a pharmacy mix a drug from raw ingredients for an individual patient. It is not approval — the FDA does not validate safety or efficacy for any specific use — but it legitimizes the supply chain.

On the table were seven peptides: BPC-157, TB-500, KPV, MOTS-c, and three others⁠9. WIRED noted that at least one of the compounds is part of the so-called "Wolverine stack" — a combination of peptides and hormones promoted by podcaster Joe Rogan and a network of wellness influencers as a recovery and anti-aging regimen⁠7⁠10.

FDA career scientists recommended against every substance that came up for a vote, citing insufficient clinical evidence⁠3⁠5. NBC reported that the panel "went against the conclusions of the agency's career scientists, who said there wasn't enough evidence to support the move"⁠3. TIME called it "highly unusual" for a committee to vote against FDA staff's own advice⁠5.

The underlying problem is straightforward: peptides like BPC-157 have circulated for years in research, athletic, and underground channels, but the published human data is thin. Three of the substances have no human clinical data at all, and the other four have what the agency described as inadequate data — a claim made in the committee's lead-up coverage but not pinned to specific names in the available reporting. What is consistent across outlets is that the agency's reviewers did not believe the evidence met the bar, and the panel voted anyway.

In a highly unusual move, a U.S. Food and Drug Administration (FDA) committee voted against FDA staff's own advice in a meeting on July 23 and 24.

Coverage of the final vote does not agree on a single number. CBS, TIME, USA Today, WIRED, BioPharma Dive, and Medscape all report that six peptides were endorsed for the compounding list⁠4⁠5⁠6⁠7⁠9⁠11. NBC News, by contrast, reports that the panel recommended easing restrictions on four⁠3. The discrepancy likely reflects which peptides are counted — the agenda had seven, several were bundled or withdrawn, and not every outlet defined the slate the same way. What every report agrees on is that the recommendation went further than the agency's own staff wanted.

The peptides on the agenda are a cornerstone of Health and Human Services Secretary Robert F. Kennedy Jr.'s wider health agenda, often branded "MAHA" — Make America Healthy Again⁠9. Reporting from AP, USA Today, and the Los Angeles Times frames the meeting as a test of whether the FDA's compounding apparatus would accommodate compounds the HHS secretary has championed⁠2⁠6⁠10.

The committee itself has also been reshaped. WIRED reported that several outside experts who testified had "a vested interest in peptides," with roughly thirty speakers flagged as having industry ties — a configuration consistent with concerns that the panel stacked the deck toward endorsement⁠7. Earlier coverage had suggested that eight of the seated members held financial ties to the peptide industry; that specific figure could not be confirmed against the available reporting.

Almost nothing, immediately. The FDA is not bound by its advisory committees. Adding a substance to the 503A bulks list requires a formal rulemaking process, which historically takes the agency well over a year to complete⁠11. Compounded peptides would not become legal at the pharmacy counter the day after the vote; the supply chain that exists today — Chinese imports, gray-market websites, telehealth prescribers — is unlikely to be displaced by anything the FDA does before 2027.

The vote does, however, send a signal. It tells compounders that the agency's scientific gatekeepers can be overruled on these substances, and it tells patients and prescribers that the regulatory ceiling on these peptides is likely to rise. For a gray market already running at scale, that is the point.